844 research outputs found
Oral History Conversation with Christopher Yanov (Reality Changers)
This is an oral history conversation with Christopher Yanov (Reality Changers)
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis
The reinvigoration of the Southern Ocean carbon sink
Several studies have suggested that the carbon sink in the Southern Oceanâthe oceanâs strongest region for the uptake of anthropogenic CO2 âhas weakened in recent decades. We demonstrated, on the basis of multidecadal analyses of surface ocean CO2 observations, that this weakening trend stopped around 2002, and by 2012, the Southern Ocean had regained its expected strength based on the growth of atmospheric CO2. All three Southern Ocean sectors have contributed to this reinvigoration of the carbon sink, yet differences in the processes between sectors exist, related to a tendency toward a zonally more asymmetric atmospheric circulation. The large decadal variations in the Southern Ocean carbon sink suggest a rather dynamic ocean carbon cycle that varies more in time than previously recognized
Into the Wild of long non-coding RNAs in Gastrointestinal Stromal Tumors (GISTs) to explore new prognostic/predictive biomarkers
n/
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis
Background
It is unclear whether the course of cirrhosis and its prognosis are related to
the amount of collagen in the liver.
Aim
To determine whether fibrosis, assessed by collagen proportionate area
(CPA) in patients with compensated cirrhosis, is associated with the presence
of oesophageal varices, and predict disease decompensation during the
follow-up period.
Methods
We prospectively evaluated 118 consecutive patients with compensated cirrhosis
to correlate fibrosis, assessed by CPA in liver biopsies, with the presence
of oesophageal varices (OV) and with the rate of liver decompensation
(LD) development during a median follow-up of 72 months.
Results
At baseline 38 (32.2%) patients had OV and during the follow-up (median
72 months, IQR 47â91), 17 patients (14.4%) developed LD. The mean CPA
value was different in patients with and without OV (14.8 5.9% vs.
21.6 9.5%, P < 0.001). The best CPA cut-off for OV by area under the
receiver operating characteristic (AUROC) was â„14% and with multivariate
logistic analysis CPA was the only variable associated with OV (OR: 28.32,
95% CI: 6.30â127.28; P < 0.001). By AUROC analysis the best CPA cut-off
to predict LD was 18.0%. By Cox regression multivariate analysis CPA
â„18% (HR: 3.99, 95% CI: 1.04â11.45; P = 0.036), albumin (HR: 0.12, 95%
CI: 0.04â0.43; P = 0.001) and presence of OV (HR: 8.15, 95% CI: 2.31â
28.78; P = 0.001) were independently associated with LD.
Conclusion
Quantification of fibrosis by collagen proportionate area allows identification
of patients with compensated HCV cirrhosis with a higher likelihood of
clinically relevant portal hypertension and a higher risk of decompensation
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
Steroid nuclear receptors are known to be involved in the regulation of epithelial-mesenchymal transition process with important roles in invasion and metastasis initiation. Androgen receptor (AR) has been extensively studied, but its role in relation to breast cancer patient prognosis remains to be clarified. AR/ER ratio has been reported to be an unfavorable prognostic marker in early primary breast cancer, but its role in the patients with advanced disease has to be cleared. We retrospectively analyzed ER, PgR, and AR expression on a case series of 159 specimens of primary BC samples by using immunohistochemistry and 89 patients of these had luminal tumors for which AR and ER expression and survival data were available. For twenty-four patients both primary and metastatic tumors were available. A significantly shorter overall survival was observed in primary tumors with AR/PgR ratio 65 1.54 (HR = 2.27; 95% CI 1.30-3.97; p = 0.004). Similarly OS was significantly shorter when ER/PgR ratio 652 in primary tumors (HR = 1.89; 95% CI 1.10-3.24; p = 0.021). The analysis of the 24 patients who had biomarker determinations both in primary tumors and metastasis showed a better OS when AR/ER ratio in the metastasis was 65 0.90 (p = 0.022). Patients with a high AR/ER ratio in primary tumor that remained high in the metastasis had better prognosis in terms of OS (p = 0.011). Despite we suggested that the ratios AR/ER and AR/PgR could be used to identify patients with different prognosis, their real value needs to be better clarified in different BC settings through prospective studies
Nintedanib in NSCLC: Evidence to date and place in therapy
The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients
Background: This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients. Methods: Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status 641 and measurable disease were enrolled. Treatment consisted of FDR gemcitabine at 800 mg/m 2 on days 1 and 8 every 21 days with capecitabine administered orally b.i.d. in equal doses (650 mg/m 2 b.i.d.) for 14 days (28 doses). Results: Between May 2005 and February 2009, 30 patients were enrolled. The median age was 67 years (45-76) and there were 14 males. Thirty patients were evaluable for response and toxicity. A total of 221 cycles were administered (median 7, range 2-16). One patient achieved complete response and 7 patients achieved partial response, giving an overall response rate of 26.7% in the intention-to-treat population. Twelve patients (40.0%) had stable disease. The median progression-free survival was 6.33 months. The median overall survival was 10.8 months. Grade 3/4 neutropenia and thrombocytopenia were noted in 13 and 7% of the patients, respectively. Grade 2/3 nonhematologic toxicities were asthenia (54% of patients), diarrhea (17%), stomatitis (23%) and hand-foot syndrome (7%). There was no treatment-related death. The drugs taken were skipped at least once in 45% of the patients and the dose was reduced in 26% of them. Conclusions: The combination of FDR gemcitabine and capecitabine in this 3-week cycle is safe and seems to have a good activity in advanced biliary cancer
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?
Objective: The vast majority of pancreatic cancers occurs sporadically. The
discovery of frequent variations in germline gene copy number can significantly
influence the expression levels of genes that predispose to pancreatic
adenocarcinoma. We prospectively investigated whether patients with
sporadic pancreatic adenocarcinoma share specific gene copy number
variations (CNVs) in their germline DNA.
Patients and methods: DNA samples were analyzed from peripheral
leukocytes from 72 patients with a diagnosis of sporadic pancreatic adenocarcinoma
and from 60 controls using Affymetrix 500K array set. Multiplex
ligation-dependent probe amplification (MLPA) assay was performed using
a set of self-designed MLPA probes specific for seven target sequences.
Results: We identified a CNV-containing DNA region associated with pancreatic
cancer risk. This region shows a deletion of 1 allele in 36 of the 72 analyzed
patients but in none of the controls. This region is of particular interest since it
contains the YTHDC2 gene encoding for a putative DNA/RNA helicase, such
protein being frequently involved in cancer susceptibility. Interestingly,
82.6% of Sicilian patients showed germline loss of one allele.
Conclusions: Our results suggest that the YTHDC2 gene could be a potential
candidate for pancreatic cancer susceptibility and a useful marker for early
detection as well as for the development of possible new therapeutic strategies
Cognitive and language performance predicts effects of spelling intervention and tDCS in Primary Progressive Aphasia
Predictors of treatment effects allow individual tailoring of treatment characteristics, thereby saving resources and optimizing outcomes. Electrical stimulation coupled with language intervention has shown promising results in improving language performance in individuals with Primary Progressive Aphasia (PPA). The current study aimed to identify language and cognitive variables associated with response to therapy consisting of language intervention combined with transcranial direct current stimulation (tDCS). Forty individuals with PPA received written naming/spelling intervention combined with anodal tDCS or Sham, using a between-subjects, randomized design, with intervention delivered over a period of 3 weeks. Participants were assessed using a battery of neuropsychological tests before and after each phase. We measured letter accuracy during spelling of trained and untrained words, before, immediately after, 2 weeks, and 2 months after therapy. We used step-wise regression methods to identify variables amongst the neuropsychological measures and experimental factors that were significantly associated with therapy outcomes at each time-point. For trained words, improvement was related to pre-therapy scores, in RAVLT (5 trials sum), pseudoword spelling, object naming, digit span backward, spatial span backward and years post symptom onset. Regarding generalization to untrained words, improvement in spelling was associated with pseudoword spelling, RAVLT proactive interference, RAVLT immediate recall. Generalization effects were larger under tDCS compared to Sham at the 2-month post training measurement. We conclude that, for trained words, patients who improve the most are those who retain for longer language skills such as sublexical spelling processes (phoneme-to-grapheme correspondences) and word retrieval, and other cognitive functions such as executive functions and working memory, and those who have a better learning capacity. Generalization to untrained words occurs through improvement in knowledge of phoneme-to-grapheme correspondences. Furthermore, tDCS enhances the generalizability and duration of therapy effects
- âŠ